Cited 38 times in
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김종윤 | - |
dc.contributor.author | 김태훈 | - |
dc.contributor.author | 박희남 | - |
dc.contributor.author | 엄재선 | - |
dc.contributor.author | 유희태 | - |
dc.contributor.author | 이문형 | - |
dc.contributor.author | 정보영 | - |
dc.contributor.author | 김대훈 | - |
dc.date.accessioned | 2019-01-15T16:49:42Z | - |
dc.date.available | 2019-01-15T16:49:42Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0039-2499 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/166665 | - |
dc.description.abstract | Background and Purpose- Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial fibrillation. Concerns have been raised about an excess of stroke among patients with creatinine clearance (CrCl) >95 mg/mL treated with edoxaban. We assessed the real-world effectiveness and safety of edoxaban in atrial fibrillation patients in relation to CrCl. Methods- In the Korean National Health Insurance Service data during the period from January to December 2016, we identified 9537 edoxaban-treated patients. Effectiveness and safety outcomes were compared between high-dose edoxaban regimen (HDER, 60 mg daily, n=2840) and a propensity score-matched warfarin group (n=2840) and between low-dose edoxaban regimen (LDER, 30 mg daily, n=3016) and matched warfarin group (n=3016). Results- The median follow-up period was 5.0 months (interquartile range, 2-7 months). The mean age was 68 years, and 63% were men in HDER group, and the mean age was 73 years, and 52% were men in LDER group. Compared with warfarin, both HDER and LDER significantly decreased the risk for ischemic stroke or systemic embolism (S/SE; HDER: adjusted hazard ratio [aHR], 0.44; 95% CI, 0.31-0.64; LDER: aHR, 0.57; 95% CI, 0.42-0.78), major bleeding (HDER: aHR, 0.40; 95% CI, 0.26-0.61; LDER: aHR, 0.61; 95% CI, 0.43-0.85), and mortality (HDER: aHR, 0.34; 95% CI, 0.22-0.53; LDER: aHR, 0.55; 95% CI, 0.41-0.73). In patients with CrCl >95 mL/min, the incidence of S/SE was higher with LDER than warfarin and comparable between HDER and warfarin group. There was lower effectiveness for the prevention of S/SE with LDER compared with warfarin at higher CrCl levels ( P for interaction=0.023). Conclusions- In real-world practice, both doses of edoxaban were associated with reduced risks for S/SE, major bleeding, and mortality compared with warfarin. LDER had lower effectiveness for the prevention of S/SE compared with warfarin at higher levels of CrCl (>95 mL/min). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.relation.isPartOf | STROKE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hee Tae Yu | - |
dc.contributor.googleauthor | Pil-Sung Yang | - |
dc.contributor.googleauthor | Tae-Hoon Kim | - |
dc.contributor.googleauthor | Eunsun Jang | - |
dc.contributor.googleauthor | Daehoon Kim | - |
dc.contributor.googleauthor | Jae-Sun Uhm | - |
dc.contributor.googleauthor | Jong-Youn Kim | - |
dc.contributor.googleauthor | Hui-Nam Pak | - |
dc.contributor.googleauthor | Moon-Hyoung Lee | - |
dc.contributor.googleauthor | Gregory Y.H. Lip | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.identifier.doi | 10.1161/STROKEAHA.118.021387 | - |
dc.contributor.localId | A00926 | - |
dc.contributor.localId | A01085 | - |
dc.contributor.localId | A01776 | - |
dc.contributor.localId | A02337 | - |
dc.contributor.localId | A02535 | - |
dc.contributor.localId | A02766 | - |
dc.contributor.localId | A03609 | - |
dc.relation.journalcode | J02690 | - |
dc.identifier.eissn | 1524-4628 | - |
dc.identifier.pmid | 30355093 | - |
dc.identifier.url | https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.118.021387 | - |
dc.subject.keyword | atrial fibrillation | - |
dc.subject.keyword | edoxaban | - |
dc.subject.keyword | heart failure | - |
dc.subject.keyword | myocardial infarction | - |
dc.subject.keyword | stroke | - |
dc.subject.keyword | warfarin | - |
dc.contributor.alternativeName | Kim, Jong Youn | - |
dc.contributor.affiliatedAuthor | 김종윤 | - |
dc.contributor.affiliatedAuthor | 김태훈 | - |
dc.contributor.affiliatedAuthor | 박희남 | - |
dc.contributor.affiliatedAuthor | 엄재선 | - |
dc.contributor.affiliatedAuthor | 유희태 | - |
dc.contributor.affiliatedAuthor | 이문형 | - |
dc.contributor.affiliatedAuthor | 정보영 | - |
dc.citation.volume | 49 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 2421 | - |
dc.citation.endPage | 2429 | - |
dc.identifier.bibliographicCitation | STROKE, Vol.49(10) : 2421-2429, 2018 | - |
dc.identifier.rimsid | 57936 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.